A thymic peptide complex originally isolated from bovine thymus gland with immunomodulatory and longevity-promoting properties studied extensively in Russian gerontology.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Thymalin is a polypeptide complex derived from the thymus glands of young calves through a standardized extraction and purification process involving enzymatic hydrolysis under carefully controlled conditions. It is not a single defined peptide sequence but a physiologically characterized mixture of low-molecular-weight polypeptides — predominantly tetrapeptides and shorter fragments — along with free amino acids that collectively exhibit thymic hormonal activity in vivo. The compound was developed and has been used extensively within Russian medicine since the 1970s, emerging from the pioneering work of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, one of the most productive centers for peptide bioregulator research in the world.
The biological rationale for thymalin is rooted in the concept of “peptide bioregulation” — the principle, advanced extensively by Khavinson and colleagues, that short peptide fragments derived from specific tissues can normalize the function of the glands and systems from which they originate. Applied to the thymus, the premise is that the declining thymic output seen with advancing age — thymic involution begins in adolescence and progresses throughout adulthood — leads to progressive deterioration of T-lymphocyte production, differentiation, and peripheral immune competence. By supplying exogenous thymic polypeptides, thymalin is theorized to restore thymic signaling to immune progenitor cells, promoting more robust T-cell maturation and immune system reconstitution in the aging or immunologically depleted host.
Thymalin holds a recognized pharmaceutical status in Russia and several post-Soviet countries, where it has been used in clinical settings for immune deficiency states, recovery from infection, post-chemotherapy immune support, and as a component of anti-aging and longevity-focused medical programs. It is not approved by the FDA or EMA, and outside of Russia and affiliated markets, its use is primarily research-oriented. It is closely related to but distinct from thymosin alpha-1 (a fully characterized thymic peptide with separate global development history) and from thymostimulin (another thymic extract product). Within the peptide bioregulator framework, thymalin is typically paired with Epithalon — a pineal-derived tetrapeptide — as a complementary immunological and anti-aging intervention.
For educational context on thymic peptides and related immunomodulatory compounds, explore the Peptide Database or use the AI Coach for detailed mechanistic comparisons.
The primary immunological mechanism of thymalin operates at the level of early T-lymphocyte development within the thymic microenvironment. Thymopoiesis — the process of T-cell maturation from bone marrow-derived CD34+ progenitors — depends critically on a series of instructive signals from thymic epithelial cells, mediated through direct cell contact and soluble thymic hormones including thymopoietin, thymulin (serum thymic factor), and thymosin alpha-1. These factors guide the sequential acquisition of T-cell receptor (TCR) components and co-receptor molecules as progenitors mature from double-negative (CD4-/CD8-) precursors through double-positive (CD4+/CD8+) intermediates to single-positive CD4+ helper or CD8+ cytotoxic mature T-cells. Thymalin’s polypeptide mixture contains fragments with sequence similarity to endogenous thymic hormones that appear to provide analogous differentiation signals to progenitor cells. At the molecular level, thymalin exposure has been shown to enhance expression of CD3 — the invariant signaling complex associated with the T-cell receptor — as well as CD4 and CD8 co-receptors, on thymocytes in culture and in vivo. This marker expression is not merely cosmetic: CD3 surface density correlates directly with TCR signaling competence, and appropriate CD4/CD8 segregation is essential for MHC-restricted antigen recognition. By restoring the thymic hormonal milieu that supports these differentiation events — particularly in aging individuals whose endogenous thymic hormone production is diminished — thymalin effectively reinvigorates the T-cell production pipeline.
One of the clinically significant immunological outcomes associated with thymalin treatment is the normalization of peripheral T-cell subset ratios, particularly the CD4+/CD8+ ratio. In healthy young adults, this ratio typically falls between 1.5 and 2.5; it declines with age as the pool of CD8+ memory T-cells expands (reflecting a lifetime of antigen encounters) while fresh thymic output of naïve CD4+ T-cells diminishes. In immunocompromised states — including HIV infection, post-transplant immune suppression, post-chemotherapy lymphopenia, and advanced aging — the CD4/CD8 ratio becomes a critical clinical parameter reflecting the capacity for coordinated adaptive immune responses. Thymalin treatment in elderly and immunologically depleted subjects has consistently been associated with increased CD4+ counts and a more balanced CD4/CD8 ratio, suggesting that the compound promotes selective enhancement of helper T-cell output rather than globally expanding all T-cell subsets. In parallel, thymalin influences innate immune function through effects on natural killer (NK) cells. NK cells are cytotoxic lymphocytes that do not require antigen-specific priming and play critical roles in tumor surveillance and early anti-viral defense. Thymalin treatment has been shown to upregulate expression of the high-affinity interleukin-2 receptor (IL-2R; CD25) on NK cells, sensitizing them to IL-2-mediated activation signals and enhancing their cytotoxic capacity against target cells. This NK cell sensitization mechanism provides an innate immune complement to the adaptive T-cell effects, potentially contributing to the observed improvements in infection resistance and tumor surveillance in treated subjects.
Beyond its direct effects on lymphocyte maturation and activation, thymalin exerts systemic immunological effects through modulation of the cytokine network — the complex intercellular signaling system that coordinates immune responses across multiple cell types and anatomical compartments. A characteristic feature of immunosenescence is the chronic low-grade inflammatory state termed “inflammaging”: persistent elevation of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6 arising from accumulating senescent cells, dysregulated macrophage activation, and declining regulatory T-cell activity. This inflammaging state drives accelerated organ aging and contributes to the increased susceptibility to infectious, neoplastic, and chronic inflammatory disease observed in elderly individuals. Thymalin treatment has been associated with reductions in circulating pro-inflammatory cytokines and elevation of anti-inflammatory signals including IL-10 and TGF-beta, shifting the cytokine balance toward a more regulated, less chronically activated state. The mechanistic pathway from thymic peptide supplementation to systemic cytokine rebalancing likely involves multiple intermediaries: restored regulatory T-cell (Treg) output from the thymus (since Treg differentiation requires proper thymic hormonal signaling), normalized helper T-cell cytokine polarization, and potentially direct effects of thymalin peptides on innate immune cell cytokine production. This capacity to address the upstream thymic hormonal deficit driving inflammaging — rather than simply suppressing cytokines pharmacologically as anti-inflammatory drugs do — represents the distinctive mechanistic contribution of thymic bioregulator therapy to the anti-aging immunology field.
The most extraordinary and frequently cited piece of evidence in thymalin’s research profile is a long-term prospective study conducted by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, examining thymalin’s effects on mortality in a geriatric population over a 15-year observation period. The study enrolled elderly men and women (average age 66–74 at baseline) who were residents of geriatric care facilities and were randomized to receive either thymalin injections (administered in annual treatment courses) or standard care without thymalin. Follow-up mortality data were collected over the subsequent 15 years. The thymalin-treated group demonstrated a cumulative survival advantage that became progressively more pronounced over time, with approximately 2-fold lower mortality rates in the treated cohort compared to controls at the 15-year endpoint. The treated group also showed slower deterioration in functional immune parameters — including T-cell counts, NK cell activity, and antibody responses to vaccination — over the follow-up period. This study, while not conducted under the methodological standards of a contemporary Western Phase 3 clinical trial — randomization methods, blinding procedures, and statistical reporting practices differ from current FDA/EMA expectations — remains a remarkable piece of long-term gerontological data for a peptide-based intervention. The magnitude and duration of the apparent mortality benefit has fueled continued interest in thymalin as a longevity-promoting agent, while also motivating calls for prospective replication in independently designed trials with modern methodology.
The immunosuppression following cytotoxic chemotherapy is one of the most clinically significant risk factors for treatment-related morbidity and mortality in cancer patients. Lymphopenia following chemotherapy — characterized by depletion of both innate and adaptive immune effectors — typically persists for weeks to months and substantially increases infection susceptibility during a period when patients are often receiving continued intensive treatment. Thymalin has been studied in cancer patients receiving chemotherapy for its potential to accelerate immune reconstitution. Clinical studies, primarily from Russian oncology centers, have shown that thymalin administration during and after chemotherapy courses is associated with faster recovery of total lymphocyte counts, CD3+/CD4+/CD8+ T-cell subsets, and NK cell activity compared to patients receiving chemotherapy alone. Infectious complications — including bacterial infections requiring antibiotic treatment and opportunistic fungal infections — were reported at lower rates in thymalin-treated patients in several studies. These findings are clinically meaningful because they suggest thymalin may complement the immune recovery that occurs naturally after chemotherapy ends, potentially by stimulating the thymus to produce new naïve T-cells at an accelerated rate. Whether thymalin treatment during chemotherapy has any impact on cancer treatment outcomes (tumor response, recurrence, or survival) has not been definitively established and would require large, carefully designed trials to address.
Among the most distinctive aspects of Khavinson’s research program is the systematic investigation of thymalin in combination with Epithalon — a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland extract epithalamine. The rationale for this combination is grounded in the peptide bioregulator theory: thymalin addresses immune senescence through thymic restoration, while Epithalon addresses neuroendocrine aging through pineal-hypothalamic pathway normalization, including melatonin production support. In combination studies in elderly subjects, the thymalin-Epithalon regimen produced improvements across a broader panel of aging biomarkers than either agent alone, including immune function indices, antioxidant enzyme activity, telomerase activity, and hormonal parameters including cortisol-to-DHEA ratios. The combination has been reported to produce more consistent stabilization of age-related functional decline than thymalin or Epithalon alone in the long-term geriatric study cohorts, supporting the concept that multi-system bioregulator intervention addresses aging’s multi-dimensional biology more comprehensively than single-target approaches. This combination approach has become a standard protocol in Russian anti-aging medicine and is increasingly discussed in international longevity medicine circles, though it has not been evaluated in large-scale Western clinical trials.
Beyond oncology and aging applications, thymalin has been studied in patients with chronic infectious conditions associated with immune dysfunction, including recurrent respiratory infections, chronic viral hepatitis, and states of secondary immune deficiency arising from prolonged illness, surgery, or trauma. In patients with recurrent upper respiratory infections attributed to diminished T-cell immunity, thymalin treatment courses have been reported to reduce infection frequency and severity over the subsequent observation period, consistent with the enhanced T-cell output and NK cell activation mechanisms described earlier. In chronic hepatitis B and C patients — conditions involving significant T-cell exhaustion and dysregulated immune activation — thymalin has been used as an adjunct to antiviral therapy with reported improvements in CD4+ counts and normalization of T-cell subset ratios. The compound’s use in post-surgical immune depression — where the physiological stress response and operative trauma transiently suppress T-cell function — has been evaluated in perioperative protocols, with studies suggesting accelerated immune function recovery in thymalin-treated patients compared to surgery-alone controls. These infectious disease applications, while not as extensively documented as the aging and oncology data, reflect the consistent immunorestorative principle that drives thymalin’s therapeutic concept across multiple immune-depleted clinical settings.
In Russian clinical practice and in the approved prescribing information from manufacturers including NPC RIBOpharm (one of the principal producers), thymalin is administered via intramuscular injection. Standard dosing protocols call for 5–20 mg per injection, with the specific dose and duration of each treatment course tailored to the indication and the degree of immune deficiency. For most applications, thymalin is given as a daily intramuscular injection for 5–10 consecutive days, constituting one treatment course. The lyophilized (freeze-dried) powder is reconstituted immediately before injection using isotonic saline or the diluent supplied with the product — typically reconstituting to a concentration of 5–10 mg/mL for injection. Reconstituted solution should be used immediately and not stored. Annual treatment cycles — meaning repeat courses given once or twice per year — have been the standard approach in the aging and longevity studies, reflecting the premise that periodic thymic stimulation supports sustained immune competence without creating dependence or desensitization. For dosing calculators applicable to peptide injection protocols, visit our peptide calculators.
Within the longevity medicine framework where thymalin is most frequently discussed in Western research communities, published protocols from Khavinson and colleagues typically describe treatment courses of 10 mg daily for 10 days, given once or twice per year. This cycle-based approach contrasts with the daily chronic administration used for some other peptide bioregulators and reflects an empirically derived protocol from the decades-long clinical and research experience at the St. Petersburg Institute. Some practitioners working in the peptide bioregulator tradition have explored modified protocols — including 5 mg daily for 5 days per quarter — but these represent adaptations of the core protocol rather than independently validated regimens. The combination protocol with Epithalon typically involves administering both peptides concurrently during the same treatment course, leveraging their complementary mechanisms during the treatment window. Any use outside of approved clinical settings must be approached with appropriate medical oversight.
Thymalin is supplied as a sterile lyophilized powder in single-dose vials of 10 mg, typically supplied in boxes of 5 or 10 vials. Reconstitution uses 1–2 mL of sterile isotonic saline (0.9% NaCl) per vial, yielding a solution suitable for intramuscular injection. The reconstituted solution should be clear or very faintly yellowish with no visible particulate matter. Injection site is typically the gluteal muscle (upper outer quadrant) or the lateral thigh, using standard intramuscular injection technique with appropriate needle length for body habitus. Site rotation across repeated daily injections within a course minimizes local tissue irritation. The lyophilized product should be stored refrigerated at 2–8°C and protected from light; reconstituted solution is not stable for storage. Standard aseptic technique is required throughout preparation and administration. For questions about injection technique and protocol implementation, the AI Coach provides educational guidance.
Thymalin is not indicated and is not studied in pregnant or lactating women; its effects on fetal or neonatal immune development are unknown and the theoretical risks of immunomodulation during these sensitive developmental periods preclude use. Use in children has been described in the pediatric immunology literature from Russian centers — particularly for primary immune deficiency states and post-infectious immune reconstitution — but no standardized pediatric dosing protocol has been established that meets contemporary Western regulatory standards. Theoretical contraindications include autoimmune conditions where enhanced T-cell activation could worsen disease; while thymalin’s CD4/CD8 ratio normalization includes effects on regulatory T-cells that could theoretically restrain autoimmunity, the net immunostimulatory effect in active autoimmune disease warrants caution. Thyroid autoimmune conditions and other organ-specific autoimmune diseases should be assessed individually before thymalin use. No significant drug-drug interactions have been formally characterized, though concurrent use with immunosuppressive agents would logically oppose thymalin’s immunostimulatory actions.
The safety profile of thymalin across several decades of clinical use in Russia and the published research literature is generally characterized as favorable, with a low incidence of significant adverse events at recommended doses. The most commonly reported adverse effects are local reactions at the intramuscular injection site — mild soreness, redness, and occasional small induration — which are expected consequences of intramuscular biological product injection and typically resolve within 24–48 hours without intervention. Systemic allergic reactions have been reported infrequently; mild urticaria or flushing occasionally occurring shortly after injection, which generally respond to antihistamine treatment. The biological origin of thymalin (calf thymus) means patients with bovine protein sensitivity could be at elevated risk for allergic reactions, and a skin test or first-dose observation period in potentially sensitized individuals is prudent. Transient febrile responses following injections — low-grade temperature elevation — have been reported in a small proportion of patients, consistent with the compound’s immunostimulatory activity rather than an infection signal, and typically self-limiting within 24 hours.
Because thymalin’s mechanism involves potentiation of T-lymphocyte activity and cytokine production, specific safety considerations apply in populations where enhanced immune activation carries risk. In patients with pre-existing autoimmune conditions — including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and multiple sclerosis — thymalin’s immunostimulatory effects could theoretically exacerbate disease activity. Although the compound’s ability to restore Treg numbers might provide a counterbalancing anti-inflammatory effect, clinical data in autoimmune populations are insufficient to characterize the risk-benefit balance, and use in active autoimmune disease is generally not recommended. In organ transplant recipients receiving immunosuppression to prevent rejection, thymalin would be expected to antagonize the intended immunosuppression, and concurrent use is contraindicated. In cancer patients, there is a theoretical concern that enhanced T-cell and NK cell activation could either benefit (through increased anti-tumor immunity) or potentially harm (through immune-mediated tissue injury) depending on the specific cancer type, immune context, and concurrent treatments — this complex oncological risk-benefit assessment requires individualized clinical evaluation.
The long-term safety record of thymalin draws from more than five decades of use in Russian clinical medicine and the published research program from the St. Petersburg Institute. The Khavinson mortality study cohort — followed for 15 years — provides the longest systematic safety observation for thymalin in humans, and no unexpected long-term adverse events were identified in these cohorts. However, the research quality considerations that apply to efficacy data also apply to the safety database: the studies were conducted under research and clinical standards that differ from contemporary GCP (Good Clinical Practice) requirements, and formal pharmacovigilance reporting systems equivalent to those in FDA-regulated markets were not in place for the duration of historical use. For researchers and clinicians considering thymalin in contexts outside of its approved Russian market indications, the absence of a formal Western regulatory safety assessment means that the available safety evidence must be interpreted within this historical and methodological context. The Peptide Database tracks the evolving safety data for thymalin and related thymic bioregulators as new publications emerge.
Thymosin alpha-1 (thymalfasin, sold as Zadaxin) is a fully characterized, synthetic 28-amino-acid peptide corresponding to a specific sequence within the prothymosin alpha protein originally isolated from thymic tissue. It has defined pharmacokinetic and pharmacodynamic properties and has been approved in some countries for chronic hepatitis B and as an immunostimulant. Thymalin is a complex biological extract — not a single defined peptide — containing multiple polypeptide fragments and amino acids from calf thymus hydrolysis. Both are “thymic” in origin and both have immunostimulatory properties, but they are distinct products with different compositions, manufacturing processes, and evidence bases. They should not be considered interchangeable.
Thymalin was primarily developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology — a research institution that has been the world’s most prolific producer of peptide bioregulator research for several decades. Khavinson, who has published over 700 papers on peptide bioregulators and holds several hundred patents on peptide-based therapeutics, developed thymalin as part of a broader program of tissue-specific peptide bioregulators including Cortagen (brain), Vilon (immune modulator), Epithalon (pineal), and numerous others targeting specific organ systems. The Soviet and later Russian medical establishment provided institutional support for this research through the military medical academy and gerontology institutes in St. Petersburg.
No. Thymogen is a synthetic dipeptide (Glu-Trp) derived from thymalin’s most active component fractions, developed as a more defined and reproducible alternative for some indications. Thymomodulin is a different thymic extract product developed in Italy (marketed as Leucotrofina) with its own distinct manufacturing process and clinical evidence base. These are related but distinct products within the broader category of thymic immunomodulator preparations. The peptide bioregulator field has a complex taxonomy of related thymic products, and distinguishing between them requires attention to the specific manufacturer, manufacturing method, and composition for each product name.
The more precise and defensible claim from the available evidence is that thymalin can partially restore markers of immune function that decline with age — including T-cell subset ratios, NK cell activity, and thymic output markers — toward values more typical of younger adults, and that this restoration is associated with measurable health outcomes including reduced infection rates and, in Khavinson’s long-term study, reduced mortality. Whether this constitutes “reversing” immune aging versus “compensating for” age-related thymic involution is partly a semantic distinction. True thymic regeneration — restoring the actual glandular tissue and its cellular architecture — has not been demonstrated with thymalin; the compound appears to stimulate residual thymic function and peripheral T-cell homeostasis rather than physically rebuilding atrophied thymic tissue.
In the combined protocols from Khavinson’s group, thymalin and Epithalon are administered concurrently during the same treatment course — typically 10 days of intramuscular injections with both compounds given daily (thymalin in the morning, Epithalon in the evening by some protocols; or as separate injection sites on the same daily schedule by others). The two compounds are not mixed in the same syringe. The rationale is that thymic (immune) and pineal (neuroendocrine-circadian) systems undergo parallel age-related decline and that addressing both simultaneously produces more comprehensive bioregulatory normalization. Annual or twice-annual repetition of this combined course is the standard protocol in Russian anti-aging medicine programs.
In Russia and the other post-Soviet countries where thymalin holds regulatory approval, it is a prescription pharmaceutical product requiring a physician’s prescription for legitimate procurement and use. Outside these markets — including the US, EU, UK, Canada, and Australia — thymalin has no regulatory approval and is not available through licensed pharmaceutical channels. Any material marketed as thymalin through supplement or research chemical channels in these jurisdictions operates outside pharmaceutical regulatory oversight, with unknown purity, sterility, and composition. Given that thymalin is an injectable biological product, obtaining it from unlicensed sources carries significant safety risks related to contamination and dosing accuracy.
The evidence for thymalin’s longevity effects — particularly the 15-year mortality study — is intriguing and mechanistically plausible but does not meet the evidentiary standards required for regulatory approval in Western markets. The Khavinson studies are generally single-center, conducted by the investigators who developed the compounds, and use methodological frameworks that differ from contemporary GCP standards regarding randomization, blinding, outcome adjudication, and statistical reporting. This does not mean the findings are false, but it does mean they require independent replication in rigorously controlled trials before firm efficacy conclusions can be drawn. The peptide bioregulator literature as a whole has not been subjected to the scale of independent academic replication applied to approved pharmaceuticals, and this evidence gap is a legitimate scientific consideration.
Immunosenescence — the aging of the immune system — is an established and active research area linking age-related thymic involution to increased infection susceptibility, reduced vaccine responsiveness, and elevated cancer risk in older adults. Thymalin’s approach of thymic hormonal supplementation to counteract involution is conceptually aligned with more recently developed approaches including thymosin beta-4, sex hormone manipulation to slow thymic regression, and gene therapy strategies to induce thymic regeneration being explored by groups like the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial investigators. Thymalin represents the earliest clinical implementation of the immunosenescence reversal concept, and understanding its research history provides valuable context for the broader field. The AI Coach can provide comparative summaries of thymalin and more recently developed immunosenescence interventions.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.